However, there are no evidence of specific safety concerns related to the COVID-19 vaccine in individuals with NF. Many people with neurofibromatosis have concerns about whether their NF diagnosis places them at high risk of side effects from the COVID-19 vaccine. The Japanese Ministry of Health, Labour and Welfare grants ODD to medicines intended for the treatment of diseases that affect fewer than 50,000 patients in Japan and for which there is a high unmet medical need. For instance, in June 2020, AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1). Moreover, increasing demand for safe and effective treatment for NF1 is expected to augment the growth of the neurofibromatosis type-1 market.
For instance, according to the National Cancer Institute, because NF1 is relatively rare, around 1 in 2,500 to 3,000 people are thought to be living with the condition, it is unlikely for any hospital or clinic to come across more than a handful of individuals with NF1. Increasing cases of neurofibromatosis type-1 around the world is expected to propel growth of the neurofibromatosis type-1 market during the forecast period. Major players operating in the global neurofibromatosis type-1 market are Healx, AstraZeneca PLC, Merck & Co., Inc, Pharm Tech Corporation, and NFlection Therapeutics, among others.
0 kommentar(er)
